Autologous stem cell transplantation for primary refractory Hodgkin's disease: Results and clinical variables affecting outcome

Annals of Oncology

Volumn 14, Issue 5, 2003, Pages 745-751

  Constans, M ^a   Sureda, A ^a   Terol, M J ^b   Arranz, R ^c   Caballero, M D ^d   Iriondo, A ^e   Jarque, I ^f   Carreras, E ^g   Moraleda, J M ^h   Carrera, D ⁱ   Leon A ^j   Lopez A ^k   Albo C ^l   Diaz Mediavilla J ^m   Fernandez Abellan P ⁿ   Garcia Ruiz J C ^o   Hernandez Navarro F ^p   Mataix, R ^q   Petit, J ^r   Pascual, M J ^s   Rifon J ^t   Garcia Conde J ^b   Fernandez Ranada J M ^c   Mateos, M V ^d   Sierra, J ^a   Conde, E ^e   more..

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^c HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^d HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^e HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^f HOSPITAL UNIVERSITARIO LA FE   (Spain)

^g HOSPITAL CLÍNIC   (Spain)

^h HOSPITAL MORALES MESEGUER   (Spain)

ⁱ HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^j HOSPITAL DE JEREZ   (Spain)

^k HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^l HOSPITAL XERAL CÍES   (Spain)

^m HOSPITAL CLÍNICO SAN CARLOS   (Spain)

ⁿ HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^o HOSPITAL DE CRUCES   (Spain)

^p HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^q HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

^r HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^s HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^t UNIVERSITY CLINIC OF NAVARRA   (Spain)

more..

Author keywords

Autologous stem cell transplantation; Hodgkin's disease; Induction failure

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CARMUSTINE; CHLORMETHINE; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MELPHALAN; PREDNISONE; PROCARBAZINE; VINCRISTINE;

ADOLESCENT; ADULT; ADVANCED CANCER; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL PROTOCOL; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; HEMATOPOIETIC STEM CELL; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM MASS; PERIPHERAL CIRCULATION; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; STATISTICAL ANALYSIS; STEM CELL TRANSPLANTATION; SURVIVAL RATE; SURVIVAL TIME; SYMPTOMATOLOGY; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR REGRESSION; WHOLE BODY RADIATION;

EID: 0037767208     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdg206     Document Type: Article

References (23)

1. Longo DL, Young RC, Wesley M et al. Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol 1986; 4: 1295-1306.
2. Prosnitz LR, Farber LR, Kapp DS et al. Combined modality therapy for advanced Hodgkin's disease: 15 year follow-up data. J Clin Oncol 1988; 6: 603-612.
3. Longo DL, Duffey PL, Young RC et al. Conventional dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure. J Clin Oncol 1992; 10: 210-218.
4. Bonfante V, Santoro A, Viviani S et al. Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD. J Clin Oncol 1997; 15: 528-534.
5. Nademanee A, O'Donell MR, Snyder DS et al. High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin's disease: results in 85 patients with analysis of prognostic factors. Blood 1995; 85: 1381-1390.
6. Yahalom J, Gulati SC, Toia M et al. Accelerated hyperfractionated total-lymphoid irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for refractory and relapsing patients with Hodgkin's disease. J Clin Oncol 1993; 11: 1062-1070.
7. Chopra R, McMillan AK, Linch DC et al. The place of high dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single center 8-year study of 155 patients. Blood 1993; 81: 1137-1145.
8. Gianni AM, Siena S, Bregni M et al. Prolonged disease free survival after high-dose sequential chemo-radiotherapy and haematopoietic autologous transplantation in poor prognosis Hodgkin's disease. Ann Oncol 1991; 2: 645-653.
9. Bierman PJ, Bagin RG, Jagannath S et al. High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: long term follow-up in 128 patients. Ann Oncol 1993; 4: 767-773.
10. Yuen AR, Rosenberg SA, Hoppe RT et al. Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease. Blood 1997; 89: 814-822.
11. Horning SJ, Chao NJ, Negrin RS et al. High-dose therapy and hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices. Blood 1997; 89: 801-813.
12. Reece DE, Barnet MJ, Connors JM et al. Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol 1991; 9: 1871-1879.
13. Lancet JE, Rapoport AP, Brasacchio R et al. Autotransplantation for relapsed or refractory Hodgkin's disease: long-term follow-up and analysis of prognostic factors. Bone Marrow Transplant 1998; 22: 265-271.
14. Josting A, Katay I, Rueffer U et al. Favorable outcome of patients relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell transplantation at the time of maximal response to conventional salvage therapy (Dexa-BEAM). Ann Oncol 1998; 9: 289-295.
15. Ribrag V, Nasr F, Bouhris JH et al. VIP (etoposide, ifosfamide and cisplatinum) as a salvage intensification program in relapsed or refractory Hodgkin's disease. Bone Marrow Transplant 1998; 21: 969-974.
16. Sweetenham JW, Carella AM, Taghipour G et al. High dose therapy and autologous stem cell transplantation for adult patients with Hodgkin's disease who fail to enter remission after induction chemotherapy: results in 175 patients reported to the EBMT. J Clin Oncol 1999; 17: 3101-3109.
17. Lazarus HM, Rowlings PA, Zhang M-J et al. Autotransplants for Hodgkin's disease in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 1999; 17: 534-545.
18. Fermé C, Mounier N, Diviné M et al. Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Études des Lymphomes de l'Adulte H89 trial. J Clin Oncol 2002; 20: 467-475.
19. Carbone PP, Kaplan HD, Musshogg K et al. Report of the Committee of Hodgkin's Disease Staging. Cancer Res 1971; 31: 1860-1861.
20. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
21. Cheson BD, Horning SJ, Coiffier B et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999; 17: 1244-1253.
22. Mantel N, Haenzel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1958; 22: 719-723.
23. André M, Henry-Amar M, Pico J-L et al. Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin's disease induction failure: a case-control study. J Clin Oncol 1999; 17: 222-229.